Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 6;11(1):20. doi: 10.1038/s41419-019-2210-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a A collection of DLBCL tumours from human DLBCL tumour-bearing xenograft mice after the endpoints of each indicated treatments (n = 32). b, c Comparison of tumour volumes. Human DLBCL (OCI-Ly7)-bearing BALB/c nude mice were treated with Chidamide and Rituximab according to dosing schedules. Tumour volume was measured, calculated daily and presented as mean volume ± SD. Comparison between final and initial tumour volumes was used to evaluate treatment responses. CR complete response, PR partial response, SD stable disease, and PD progressive disease. d Comparison of tumour weights. Data shown are mean ± SD. e Kaplan Meier overall survival (OS) curves of tumour-bearing xenograft mice. Four subgroups, vehicle control treatment (n = 8), Chidamide treatment (n = 8), Rituximab treatment (n = 8) and Chidamide + Rituximab treatment (n = 8) from two independent experiments. C + R means combined treatment with both Chidamide and Rituximab. f Counteracting effect of Chidamide on Rituximab-induced down-regulation of CD20. Tumour samples were fixed and sliced and stained with H&E (the left column); histochemical chemistry staining of ac-Histone H3, Histone H3, P-HDAC3 and CD20 (the middle columns); immunofluorescent staining of CD20 (the right column). Images were taken with a Nikon microscope (original magnification ×100, ×200 and ×400). Data presented were from three independent experiments.